Outreach Signals
Publishing Details
Contact & Outreach
About This Podcast
Social Media
Explore Statistics
Recent Episodes
E221: The Diagnostic Room: The AI Governance Timeline Moved. Your Governance Exposure Didn't
On 7 May 2026, the EU reached a provisional agreement to push back the hardest deadlines in the EU AI Act. Many leadership teams heard one message: “we’ve got more time”. In this solo episode, Dr…
E220: The Intelligence Gap: Why Pharma's Biggest Deals Are Being Lost Before They Even Know They're Competing
In pharma, the biggest deals are increasingly won or lost before a formal process even begins. In this episode, Dr Andree Bates interviews Andrey Doronichev, co-founder and CEO of Bioptic, about the…
E219: Bridging the Data-Use Divide: How QuadraticMed’s Dr. Danielle Bower Bridges Medicine and Data Science to Unlock Real-World Evidence
Real world evidence (RWE) could transform drug development and clinical care, but most organisations still struggle to turn messy clinical data into decisions they can trust. In this episode, Dr…
E218: How astrophysics methods used to study dark matter are now being applied to model cancer biology
Some of the most powerful breakthroughs happen when methods built for one discipline get turned on another. In this episode, Dr Andree Bates interviews Dr Irina Babina, CEO of Concr, on how…
E217: The Diagnostic Room: Pilot purgatory: why pharma AI stalls after the first wins
Pharma doesn’t have an AI experimentation problem. It has an AI execution, scaling, and ROI justification problem. In this solo episode, Dr Andree Bates names one of the most expensive failure…
E216: When AI meets Cell Engineering
Cell therapies have huge potential, but cost, complexity, and centralised manufacturing have kept many of them confined to last-line use. In this episode, Dr Andree Bates speaks with Armon Sharei,…
E215: Location, Location, Innovation: AI Site Twins and the New Era of Site Selection
Clinical trial site selection is one of the biggest hidden bottlenecks in drug development, and it’s still often driven by legacy relationships, spreadsheets, and habit. In this episode, Dr Andree…
E214: Beyond Copilot
For many life sciences teams, the first wave of AI has looked like copilots: smart search, quick answers, and help on demand. Useful, but passive. In this episode, Dr Andree Bates is joined by Parth…
E213: The Diagnostic Room: We have AI initiatives, but do we have a strategy? The quickest self-test
Many pharma and life science organisations have been investing in AI for years: pilots across commercial, medical, regulatory, and R&D, innovation labs, steering committees, vendor spend, and…
E212: The Ethics of AI
AI ethics has moved from theory to urgent necessity, especially as AI systems become embedded in healthcare, business decisions, and society at large. In this episode, Dr Andree Bates is joined by Dr…
E211: Precision Monitoring: How Digital Biomarkers Are Changing Medicine
Digital biomarkers are turning everyday movement into clinically useful data, giving doctors a clearer picture of what’s happening between appointments, and giving pharma new ways to measure drug…
E210: Beyond Alzheimer’s: Scaling Digital Twins Across Disease Areas
Digital twins have become one of the most promising tools in Alzheimer’s research, but the bigger story is what happens when they scale across disease areas. In this episode, Dr Andree Bates…
E209: Beyond Failure Prevention: How AI is Redesigning the Drug Discovery Pipeline
AI in drug development is moving beyond “failure prevention” into something much bigger: redesigning how we discover, develop, and deliver medicines. In this episode, Dr Andree Bates speaks with…
E208 : The future of enterprise AI: agents, automation, and trust
Enterprise AI is shifting from experiments to infrastructure, and that changes everything. In this episode, Dr Andree Bates interviews Jocelyn Houle, Senior Director of Product Management at…
E207: The economics of clinical trials and the relationship to AI
Clinical trials are a massive industry with brutal economics, long timelines, and failure rates that would be unacceptable in almost any other sector. In this episode, Dr Andree Bates is joined by Dr…
EP206: Why Your Pharma AI Strategy Is Probably Broken — And What a Real Blueprint Looks Like
AI capability has never been higher, yet most pharma AI programmes are still failing to create measurable business impact. In this solo episode, Dr Andree Bates breaks down why many pharma and…
E205: Healthcare Accessibility & Innovation
Healthcare accessibility is still being held hostage by phone queues, missed calls, and clunky portals. In this episode, Dr Andree Bates sits down with Josh Taylor of TxtSquad to explore why simple,…
E204: Human-Centered AI: Designing Intelligence That Aligns With Us
As artificial intelligence becomes increasingly woven into everyday life, the real question isn’t just what AI can do — it’s what it should do for humans. In this episode, Dr Andree Bates interviews…
E203: Building Programmable Biologics from Scratch: How DenovAI's AI is Revolutionizing Drug Discovery
Designing proteins that have never existed in nature is no longer sci-fi — it’s becoming a real drug discovery strategy. In this episode, Kashif Sadiq, Founder & CEO of DenovAI Biotech, explains…
E202: Recent Advances in LLMs and How They Will Impact Science and Pharma Research
Large Language Models (LLMs) are moving far beyond text generation—and into the heart of scientific discovery and pharmaceutical research. In this episode, Javier Tordable, founder and CEO of…
Frequently Asked Questions
AI For Pharma Growth has published 223 episodes since March 2022, covering topics in Technology.
AI For Pharma Growth is currently highly active with new episodes weekly. Average episode length is 30m.
Sign up on Grep.FM to access contact details for AI For Pharma Growth, including email and social media links.
